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Abstract
Background: A significant genetic component has been described for idiopathic pulmonary fibrosis (IPF). The
R131H (rs1801274) polymorphism of the IgG receptor FcgRIIa determines receptor affinity for IgG subclasses and is
associated with several chronic inflammatory diseases. We investigated whether this polymorphism is associated
with IPF susceptibility or progression.
Methods: In a case-control study, we compared the distribution of FcgRIIa R131H genotypes in 142 patients with
IPF and in 218 controls using allele-specific PCR amplification.
Results: No differences in the frequency of FcgRIIa genotypes were evident between IPF patients and control
subjects. However, significantly impaired pulmonary function at diagnosis was observed in HH compared to RR
homozygotes, with evidence of more severe restriction (reduced forced vital capacity (FVC)) and lower diffusing
capacity for carbon monoxide (DLCO). Similarly, increased frequency of the H131 allele was observed in patients
with severe disease (DLCO < 40% predicted) (0.53 vs. 0.38; p = 0.03). Furthermore, the H131 allele was associated
with progressive pulmonary fibrosis as determined by > 10% drop in FVC and/or > 15% fall in DLCO at 12 months
after baseline (0.48 vs. 0.33; p = 0.023).
Conclusions: These findings support an association between the FcgRIIa R131H polymorphism and IPF severity and
progression, supporting the involvement of immunological mechanisms in IPF pathogenesis.
Background
Idiopathic pulmonary fibrosis (IPF) is a non-neoplastic
lung disease of unknown etiology and represents the most
common clinical entity within the group of idiopathic
interstitial pneumonias. The histological correlate of IPF is
usual interstitial pneumonia (UIP), in which areas of inter-
stitial fibrosis of various ages are interspersed with normal
lung [1,2]. This histological pattern could be explained by
repeated episodes of lung injury separated in time and
place followed by an uncontrolled wound healing response
that consequently leads to excessive fibrosis. Although for
some fibrosing interstitial lung diseases the initiating lung
injury is well defined and might include inhaled allergens,
dust, or fibers [2], in IPF the cause of the initiating lung
injury has not been identified. However, several lines of
evidence support a role for immune complexes (antibody-
antigen complexes) as mediators of lung injury in IPF that
ultimately elicit a pro-fibrotic response [3]. Normally,
immune complexes that are formed during an immune
response are rapidly cleared by tissue-resident phagocytes.
However, in many chronic inflammatory diseases elevated
levels of circulating immune complexes as well as their
deposition in tissues have been detected, which conse-
quently promote tissue injury via activation of comple-
ment and engagement of leukocyte Fc receptors [4-6]. In
the context of IPF, pulmonary fibrosis has been induced in
animals following administration of immune complexes
[3,7]. Secondly, lung fibrosis resembling IPF occurs in
patients with autoimmune rheumatic diseases, including
rheumatoid arthritis and scleroderma. Thirdly, immune
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of patients with IPF [8-16].
IgG-containing immune complexes are recognized via
Fcg receptors, which are expressed predominantly by
leukocytes. Substantial genetic variation in the form of
single nucleotide polymorphisms (SNPs) has been
described for Fcg receptor genes, and their association
with several chronic inflammatory and autoimmune dis-
eases has been reported (reviewed in [17]). The R131H
(rs1801274) substitution of FcgRIIa, a low-affinity IgG
receptor that is widely expressed by diverse leukocyte
types, maps to the receptor interface interacting with
the Fc region of IgG and determines the affinity of
FcgRIIa for human IgG subclasses [17]. The H131 but
not the R131 variant is capable of interacting with IgG2
and has been previously shown to bind and mediate
phagocytosis of IgG2-coated particles [18]. In the pre-
sent study we investigated whether the FcgRIIa R131H
polymorphism is associated with IPF disease susceptibil-
ity or progression.
Methods
Study Design and Subjects
In this case-control study, 142 IPF patients and 218 con-
trols were recruited and the FcgRIIa R131H genotype was
determined. For IPF patients, pulmonary function was
assessed at baseline and repeated at intervals over 12
months to assess disease progression. IPF patients were
categorized according to disease severity (DLCO <4 0 %
predicted at presentation) and progression (reduction of
≥10% in FVC or ≥15% in DLCO in the first 12 months).
IPF (n = 142) was diagnosed in patients attending a spe-
cialist interstitial lung disease clinic according to the
American Thoracic Society (ATS)/European Respiratory
Society (ERS) international multidisciplinary consensus
classification [2,19]. The baseline characteristics of the IPF
cohort are summarized in Table 1. Bronchoalveolar lavage
(BAL) and/or surgical lung biopsy were performed in
cases for which a confident diagnosis on clinical, func-
tional and radiological grounds was not possible. A con-
sensus diagnosis was made in each case following joint
review by two respiratory clinicians and a radiologist (and
a pathologist for cases in which biopsy was performed).
The control group (n = 218) comprised age-matched
patients (n = 70) with a number of different acute or
chronic lung pathologies other than an interstitial
lung disease, ranging from asthma and seasonal influenza
to pneumonia and lung cancer that were admitted to
Edinburgh Royal Infirmary (mean age: 71.4 ± 10.2; female/
male: 34/36) and healthy blood donors (n = 148; female/
male: 65/83). No differences in the R131H genotype fre-
quencies were evident between the control patient and
healthy donor subgroups so these two subgroups were
combined. All subjects were Caucasians. Ethical approval
was obtained from the Lothian Research Ethics Commit-
tee (LREC/2002/4/65) and informed consent was obtained
from all subjects.
Pulmonary function measurements were recorded at
baseline (first radiologic evidence for IPF) and at 6 and
12 months (± 1 month) following diagnosis to assess dis-
ease progression in 121 patients with IPF. The remaining
21 patients were lost to follow up or were unfit to per-
form serial testing.
FcgRIIa R131H Genotyping
Genomic DNA was extracted from 2 ml of peripheral
venous blood using a QIAamp DNA Blood Midi Kit (Qia-
gen) following the manufacturer’s instructions. For the
determination of FcgRIIa R131H genotypes, PCR amplifi-
cation reactions were performed using allele-specific PCR
primers (Eurofins, MWG). For the R131 allele: forward: 5’-
AAATCCCAGAAATTCTCACG,r e v e r s e :5 ’-CACTCC
TCTTTGCTCCAGTG; For the H131 allele: forward: 5’-
AAATCCCAGAAATTCTCACA,r e v e r s e :5 ’-CACTCCT
CTTTGCTCCAGTG. Primers were designed based on
the human DNA reference sequence (NCBI build 36.1).
Nucleotides in bold are allele-specific and those under-
lined indicate nucleotides deliberately mismatched to the
original gene sequences to increase primer specificity. PCR
amplification reactions were performed in 50 μl volume,
containing 200 μMd N T P ,1 . 5m MM g C l 2, 200 nM of
each primer pair (forward and reverse), 2.5 U Taq DNA
polymerase (GoTaq Flexi DNA Polymerase, Promega) in
green 1× GoTaq Flexi buffer (Promega), and 1 μlo f
extracted genomic DNA (200-500 ng). PCR amplification
conditions were 5 min at 94°C, followed by 30 cycles of 45
sec at 94°C, 45 sec at 54°C and 45 sec at 72°C and a final
extension step of 5 min at 72°C. PCR products (269 bp)
Table 1 Baseline Pulmonary Function of the IPF Cohort
Patients, n 142
Age, y (range) 70 ± 8.8 (50-87)
Gender, F/M (%) 47/95 (33.1/66.9)
FEV1, L 2.16 ± 0.6
% Predicted 87.52 ± 20.0
FVC, L 2.76 ± 0.8
% Predicted 87.65 ± 19.6
FEV1/VC, % predicted 79.07 ± 9.9
TLC, L 4.30 ± 1.0
% Predicted 74.20 ± 15.3
DLCO, ml/min/mmHg 4.11 ± 1.4
% Predicted 52.75 ± 15.9
KCO, ml/min/mmHg/L 1.10 ± 0.3
% Predicted 82.47 ± 22.8
Values as mean ± SD. Abbreviations: IPF: idiopathic pulmonary fibrosis; DLCO:
Diffusing capacity of the lung for carbon monoxide; KCO:D L COcorrected for
lung volume.
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efficiency and specificity of the allele-specific PCR amplifi-
cation was validated by direct sequencing using Applied
Biosystems Big-Dye 3.1 chemistry on an Applied Biosys-
tems model 3730 automated capillary DNA sequencer
(College of Life Sciences, University of Dundee, UK). The
number of samples analysed by direct sequencing corre-
sponded to about 10% of the total analysed samples (n =
360) with a minimum of 10 for each tested genotype (RR,
RH, HH). In all cases, the genotypes obtained from the
sequencing-based method matched those obtained by
PCR.
Genetic and Statistical Analysis
Hardy-Weinberg equilibrium was assessed by a c
2 test
with one degree of freedom. Differences in the genotype
and allele frequencies between control and IPF patients
were analysed by the c
2 or Fisher’s exact tests. The statisti-
cal power (a = 0.05) of this study to detect differences in
the minor (H131) allele frequency corresponding to odds
ratio (OR) of 2 between control and IPF groups reached
98.8%. One-way analysis of variance (ANOVA) was used
to test for differences in the mean values of quantitative
variables, and where statistically significant effects were
found post-hoc analysis using the Bonferroni test was per-
formed. Unless otherwise stated, quantitative data are pre-
sented as mean ± SD and p < 0.05 was considered to be
statistically significant. Data were analysed with GraphPad
Prism software (Graphpad) and statistical power was calcu-
lated using the GraphPad StatMate software (Graphpad).
Results
FcgRIIa R131H polymorphism does not confer
susceptibility to IPF
Both in the control and in the IPF cohort there was agree-
ment between genotypes observed and those predicted by
the Hardy-Weinberg equilibrium (controls: c
2 = 0.008, p =
0.93; IPF: c
2 = 1.83, p = 0.18). No significant differences in
the distribution and frequency of the FcgRIIA R131H gen-
otypes (RR, RH, HH) were observed between control sub-
jects and IPF patients (RR: 0.36 for control vs. 0.37 for IPF;
RH: 0.48 vs. 0.43; HH: 0.16 vs. 0.20; c
2 = 1.38, df2, p =
0.50). Allelic frequency of R131 and H131 variants in IPF
patients was comparable to those noted for the control
group (R: control vs. IPF, 0.60 vs. 0.59; H: 0.40 vs. 0.41;
p = 0.70, OR 1.07, 95% CI 0.79-1.44).
T h e s ed a t as u g g e s tt h e r ei sn od i f f e r e n c ei nt h ef r e -
quency of the FcgRIIa R131 polymorphism between con-
trol and IPF groups.
The FcgRIIa H131 variant is associated with more severe
disease at presentation
We next compared the R131H genotype frequencies
with pulmonary function measurements obtained at
presentation. Homozygous carriers of the H allele had
significantly lower FEV1 and FVC compared with RR
homozygotes (Table 2; Figure 1A-B). In addition, sub-
stantially impaired pulmonary gas transfer was observed
in H131 homozygous patients, as evidenced by signifi-
cantly reduced levels of DLCO in these patients com-
pared to RR homozygotes (Figure 1C). DLCO is a
reliable guide to outcome and values of less than 40% of
predicted are generally indicative of advanced disease
[2]. Significantly increased frequencies of the HH and
RH genotypes were evident in the IPF subgroup with
DLCO <4 0 %v s .t h o s ew i t hD L CO ≥40% (< 40% DLCO
HH: 0.25, RH: 0.56, RR: 0.19; ≥40% DLCO HH: 0.18, RH:
0.39, RR: 0.43; c
2 6.1, df2, p = 0.04). In addition, the
overall frequency of the H allele was increased in
patients with DLCO < 40% compared to those with
DLCO ≥40% predicted (0.53 vs. 0.38; p = 0.03, OR 1.87,
95% CI 1.07-3.28). Homozygotes and heterozygotes of
the H allele were associated with DLCO < 40% predicted
(p = 0.01, OR 3.23, 95% CI 1.23-8.49). Collectively, these
results indicate that the H allele is associated with
reduced pulmonary function at presentation in IPF,
which is indicative of more advanced disease.
R131H polymorphism is associated with IPF disease
progression
To further investigate IPF disease progression, serial
lung function measurements for the first 12 months fol-
lowing baseline were obtained and the percent change
in FVC and DLCO were determined.
A drop from baseline of ≥10% in FVC or ≥15% in
DLCO in the first 6-12 months is associated with higher
Table 2 Baseline Pulmonary Function of IPF Patients
According to FcgRIIa Genotypes
FcgRIIa Genotype
RR RH HH P value
Patients, n 53 61 28
Age, y 70.1 ± 8.9 70.1 ± 8.9 69.8 ± 10.5 NS
FEV1, L 2.31 ± 0.6 2.12 ± 0.6 1.96 ± 0.5 0.037
% predicted 93.0 ± 22.0 85.7 ± 17.4 81.5 ± 19.4 0.031
FVC, L 2.92 ± 0.8 2.75 ± 0.8 2.43 ± 0.6 0.026
% predicted 91.9 ± 20.6 87.1 ± 17.4 80.1 ± 20.7 0.041
FEV1/VC, % predicted 79.7 ± 9.4 77.5 ± 10.2 81.3 ± 9.7 NS
TLC, L 4.47 ± 0.9 4.82 ± 1.1 3.94 ± 1.0 NS
% predicted 76.7 ± 14.0 72.9 ± 15.8 71.8 ± 16.5 NS
DLCO, ml/min/mmHg 4.49 ± 1.4 3.98 ± 1.2 3.54 ± 1.4 0.012
% predicted 57.4 ± 15.4 51.4 ± 15.0 45.7 ± 16.4 0.007
KCO, ml/min/mmHg/L 1.17 ± 0.3 1.07 ± 0.3 1.06 ± 0.3 NS
% predicted 87.6 ± 24.6 80.1 ± 20.5 76.6 ± 22.9 NS
Values as mean ± SD. P values (P) for RR vs. HH comparison. Abbreviations:
NS: non-significant; IPF: idiopathic pulmonary fibrosis; DLCO: Diffusing capacity
of the lung for carbon monoxide; KCO:D L COcorrected for lung volume.
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[2,20-22]. Therefore, patients were categorized into
either progressive (n = 49) or non-progressive (n = 72)
groups and their association with the FcgRIIa R131H
genotypes was investigated. Significant skewing in the
distribution of the R131H genotypes (RR, RH, and HH)
was noted between progressive and non-progressive
groups (Table 3). In particular, in the progressive group
there was higher frequency of the HH genotype (0.29 vs.
0.11) as well as decreased RR genotype frequency (0.33
vs. 0.44; c
2 = 6.13, df2, p = 0.047) compared to the non-
progressive group. In addition, the frequency of the H
allele was increased in the progressive group compared
to the non-progressive group (0.48 vs. 0.33; p = 0.023,
OR 1.84, 95% CI 1.09-3.12).
Furthermore, a significant reduction in FVC was
observed in the first 12 months in HH homozygotes,
compared to homozygous and heterozygous carriers of
the R allele (Figure 2). In contrast, no major change in
DLCO was evident between the three R131H genotypes,
despite the lower baseline DLCO values observed in HH
patients (data not shown). In summary, all these findings
suggest that the FcgRIIa R131H polymorphism represents
a genetic risk factor for IPF disease progression.
Discussion
The current model of IPF pathogenesis suggests a dysre-
gulated wound-healing response with minimal inflamma-
tion in response to alveolar epithelial damage. Although
the cause of epithelial injury is unknown, immunological
Figure 1 H131 variant is associated with impaired pulmonary function at baseline.( A) FEV1 (forced expiratory volume in 1 second),
(B) FVC (forced vital capacity), and (C)D L CO (diffusing capacity of the lung for carbon monoxide) were determined in IPF patients and their
association with FcgRIIa R131H genotypes was assessed. Data are presented as the mean percent predicted value ± 95% confidence intervals
(CI). *p < 0.05 RR vs. HH, **p < 0.01 RR vs. HH.
Table 3 Genotype Frequencies and Pulmonary Function of Progressive and Non-progressive Subgroups of IPF Patients
Progressive Group Non-Progressive Group
Patients, n 49 72
Age, y (range) 70.51 ± 9.3 69.95 ± 8.9
Gender, F/M (%) 12/37 (24.5/75.5) 26/46 (36.1/63.9)
FcgRIIa Genotypes, n (%) RR 16 (32.7) 32 (44.4)
RH 19 (38.8) 32 (44.4)
HH 14 (28.6) 8 (11.1)
c
2 = 6.13, df2, p = 0.047
FcgRIIa Alleles, n (%) R 51 (52.0) 96 (66.7)
H 47 (48.0) 48 (33.3)
p = 0.023, OR 1.84, 95% CI 1.09-3.12
FEV1, L (% predicted) 2.29 ± 0.6 (90.3 ± 20.9) 2.19 ± 0.6 (89.2 ± 18.8)
FVC, L (% predicted) 2.81 ± 0.7 (86.8 ± 21.1) 2.86 ± 0.8 (91.7 ± 17.8)
FEV1/VC, % predicted 81.96 ± 9.9 77.05 ± 9.5
TLC, L (% predicted) 4.33 ± 1.0 (71.5 ± 15.6) 4.43 ± 1.0 (76.8 ± 13.5)
DLCO, ml/min/mmHg (% predicted) 4.13 ± 1.3 (52.2 ± 16.3) 4.18 ± 1.3 (53.8 ± 14.3)
KCO, ml/min/mmHg/L (% predicted) 1.08 ± 0.3 (82.7 ± 22.8) 1.10 ± 0.3 (81.7 ± 22.8)
Disease progression groups were determined based on changes in FVC or DLCO. Progressive group displayed a ≥10% decrease in FVC and/or a ≥15% decrease in
DLCO 12 months after baseline measurements. Values as mean ± SD. Abbreviations: IPF: idiopathic pulmonary fibrosis; DLCO: Diffusing capacity of the lung for
carbon monoxide; KCO:D L COcorrected for lung volume.
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[23]. In the present study, we have demonstrated that the
H131 variant of FcgRIIa is associated with disease severity
at presentation and progression over the subsequent 12
months. In particular, increased frequency of the H131
allele was observed in patients with more advanced dis-
ease (DLCO < 40% predicted). Similarly, HH homozygotes
displayed significantly impaired baseline pulmonary func-
tion compared to RR homozygotes, with evidence of
more severe restriction and reduction in gas transfer. In
addition, significant association of this allele was evident
in IPF patients with progressive disease (>10% drop in
FVC and/or >15% in DLCO).
Our data also suggest that lung function is dependent
on the number of H alleles. In particular, as illustrated
in Figure 1A-C and Table 2, baseline pulmonary func-
tion seemed to correlate with H alleles frequency in
each patient. For example, more severe restriction and
impaired gas transfer was evident in HH homozygotes
compared to RH heterozygotes, and accordingly, in RH
heterozygotes compared to RR homozygotes. This
observation suggests a dose-dependent effect for the H
allele on pulmonary function and therefore in disease
manifestation. Similarly, a dose response relationship
has been previously demonstrated for the R131 allele
and SLE [24]. Collectively, our findings suggest that the
R131H polymorphism is an additional determinant that
influences IPF severity and progression.
Previous studies on the FcgRIIa R131H polymorphism
have provided information about the functional conse-
quences of this polymorphism. Association of the H131
variant has also been previously reported for a number of
chronic inflammatory disorders, including periodontitis
and Guillain-Barré syndrome [25-27], possibly due to the
increased capacity of this variant for efficiently recognising
IgG2. Since FcgRIIa is expressed by diverse leukocyte
types, including macrophages and neutrophils which are
typically observed in the BAL fluid of IPF patients [2,17],
the R131H polymorphism is likely to influence IgG-
mediated effector responses in these cell types. Indeed,
engagement of FcgRIIa with IgG-containing immune com-
plexes initiates a number of leukocyte effector responses
including antibody-dependent cellular cytotoxicity, phago-
cytosis, production and release of proteolytic enzymes
including matrix metalloproteinases, and generation of
reactive oxygen and nitrogen intermediates [28]. Ensuing
damage to the alveolar walls and pulmonary interstitium
could lead to fibroblast activation and aberrant deposition
of fibrotic tissue which is characteristic of IPF. Accelerated
pulmonary damage and fibrosis would result in more
severe disease pathology and progression, as evidenced by
more severe lung restriction (reduced FEV1 and FVC) and
reduced gas transfer (DLCO), which in the present study
are associated with the H131 allele.
Although the ancestral allele for the R131H poly-
morphism is the H allele, in the present study the R
allele was more prevalent than the H allele. Since the
H131 allele represents the sole human leukocyte Fc
receptor allotype capable of binding to IgG2 it might
have been subject to strong evolutionary forces which
shaped R131H genotype distribution in order to confer
protection from a number of autoimmune and chronic
inflammatory disorders. This assumption is strengthened
by the fact that the frequency of the R131H genotypes
varies greatly between different ethnic groups, especially
Caucasians and Asians, suggesting the presence of dif-
ferent evolutionary forces in different populations
[29,30]. It should be noted that the genotype frequencies
observed in this study are in accordance with those
reported in several previously published studies in
Caucasian populations [29,31].
Previous studies provide evidence for a role for immune
complexes in IPF disease pathogenesis, either through
initiation of local inflammatory responses or direct media-
tion of lung injury [3,7-12,14-16,32]. Further evidence for
a role of immune complexes in IPF pathogenesis is pro-
vided by the association of IPF susceptibility with poly-
morphisms in the complement receptor 1 (CD35) gene
that is involved in the clearance of circulating immune
Figure 2 R131H polymorphism is associated with disease
progression. Serial lung function measurements were obtained for
121 IPF patients 12 months following baseline to assess disease
progression. FVC (forced vital capacity) displayed a significant fall in
HH, but not RR or RH patients. Data are presented as the mean
percent change in actual values 12 months following baseline ± 95%
confidence intervals (CI). *p < 0.01 RR vs. HH.
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firm such association in other ethnic groups [34,35].
IgG-mediated production and release of proinflammatory
cytokines by FcgRIIa-expressing leukocytes could amplify
local inflammatory responses, leading to increased leuko-
cyte infiltration [28]. A number of pro-inflammatory cyto-
kines have been detected in the BAL fluid of IPF patients,
including IL-1b, IL-4, IL-8, IL-13, TNF-a, TGF-b. Elicita-
tion of the production of key fibrogenic molecules would
accelerate fibrosis and disease progression [36-39]. Several
reports describe associations of IPF with genes involved in
proinflammatory pathways, including cytokines, chemo-
kines and their corresponding receptors, and genes
involved in tissue repair and fibrogenesis [40-49].
Conclusions
In summary, we have here reported that the FcgRIIa
R131H polymorphism is associated with IPF severity
and progression, providing additional support for the
role of immunological mechanisms in the development
of IPF. This not only supports existing evidence on the
pathogenic potential of immune complexes, but also
reveals a novel role of Fcg receptors in IPF disease pro-
gression. Given the relatively small size of the IPF
cohort investigated here, additional studies on other IPF
patients and different ethnic populations should be
undertaken to further strengthen the observed associa-
tion. Collectively, our results along with previous genetic
association studies on IPF suggest that multiple genetic
factors in combination with other environmental and
immunological triggers can influence predisposition as
well as disease progression. Identification of genetic var-
iants that affect susceptibility or progression of IPF by
altering the activity of molecules involved in inflamma-
tory and pro-fibrotic pathways provides novel insights
into the precise pathogenic mechanisms underlying IPF.
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